Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued expenses and other liabilities | (1,442) | 1,695 |
| Net cash used in operating activities | (99,817) | (69,262) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (315) | (503) |
| Proceeds from maturities of available-for-sale securities | 146,880 | 69,000 |
| Purchases of available-for-sale securities | (235,396) | (128,777) |
| Other | — | 85 |
| Net cash used in investing activities | (88,831) | (60,195) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Solid Biosciences Inc.'s capex?
- Solid Biosciences Inc. (SLDB) reported capex of $150K in Q2 2026.
- How has Solid Biosciences Inc.'s capex changed year-over-year?
- Solid Biosciences Inc.'s capex decreased by 60.2% year-over-year, from $377K to $150K.
- What is the long-term trend for Solid Biosciences Inc.'s capex?
- Over 4 years (2021 to 2025), Solid Biosciences Inc.'s capex has grown at a -2.6% compound annual growth rate (CAGR), from $1.28M to $1.15M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Solid Biosciences Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude